Anti-CTLA-4 therapy enhances the antigen-specific T cell-dependent immune response, while anti-PD-1/PD-L1 activates the ability of cytotoxic T cells to lyse cancer cells, resulting in mutually synergistic effects when delivered together [31]. The gene discussed is PDCD1; the disease is cancer.